What are Negative Enterprise Value Stocks? They’re Rare, but Very Profitable
Negative enterprise value stocks are hard to find. But having outperformed the market by more than 5-to-1, they're worth hunting for.
Read More
biotech stocks Archives
The Best Protein and DNA Stocks to Play the Sequencing Trend
Cutting-edge work is being done in protein engineering, protein sequencing and protein-analysis. Here are the best protein and DNA stocks to play the protein trend.
Read More
5 Power Fintech ETFs to Buy for 2022
The rise of financial technology has been a positive theme of late. With that in mind, these five fintech ETFs are worth your consideration.
Read More
Ultragenyx Stock: The RARE Growth Title Acting Well Right Now
Growth stocks have fallen flat in recent weeks. But there are encouraging signs of a turnaround, and Ultragenyx stock has already broken out.
Read More
3 Resilient Stocks that are Zigging While the Market Zags
While the rest of the market retreats, these three resilient stocks have been trending up. Here's why they might just be getting started.
Read More
3 Small-Cap Biotech Stocks that Could Cure Coronavirus
Biotechs around the world are scrambling to find a coronavirus vaccine. These three small-cap biotech stocks appear to be among the closest.
Read More
Investing Implications for the Best-, Base- and Worst-Case Coronavirus Scenarios
What are the investing implications of a best-, base- and worst-case scenario for Americans amid this global pandemic? Let's break it down.
Read More
The 10 Best-Performing Micro-Cap Stocks of 2019
The best-performing micro-cap stocks of 2019 can give us some insight as to what stocks (and sectors) will be the big small-company winners in 2020.
Read More
MedTech Stocks: The One Growth Market You Can’t Ignore
MedTech Stocks: Stable, Yet Defensive Growth
Medical technology, or MedTech, stocks, have long been a favorite for growth investors due to the attractive qualities of gradual, long-term growth in a relatively defensive industry. Throw in M&A potential and it’s not hard to see why group...
Read More
Daily Alert – 2/11/19
This biotech is somewhat speculative, but analysts expect it to grow by 22% annually for the next five years.
Read More
3 Small-Cap Sectors Poised for Big Growth in 2018
While small caps as a group lagged behind the broad market in 2017, these three small-cap sectors have plenty of momentum and are poised for more in 2018.
Read More
Is Buying Biotech Stocks a Good Idea?
Buying biotech stocks seems like a contrarian play at the moment. But it made one day trader a lot of money. Here's what it says about the current market.
Read More
The 5 Best Small-Cap Biotech IPOs of 2017
In a busy year for IPOs, small cap biotech IPOs have been popping up everywhere. Here are five of them that I really like.
Read More
How the Gilead-Kite Pharma Deal Is Driving Biotech Stocks
After two months of churn, biotech stocks are suddenly red-hot thanks to a blockbuster Gilead-Kite Pharma deal that's propping up the entire sector.
Read More
Why TEVA Stock Fell 40% in Three Days
Most biotechs have been red-hot, but Teva Pharmaceuticals (TEVA) just fell 40% in three days. Here's what happened to TEVA stock.
Read More
3 Soaring Small-Cap Healthcare Stocks to Buy Now
Small-cap healthcare stocks have been the best performing sector this year, and these three stocks stand above the crowd.
Read More
Where to Find the Best Biotech Stocks
The biotech sector is in full recovery mode, and the best biotech stocks are still on sale. Here's where you can find them.
Read More
How to Play Biotech Stocks After Record Breakout
Biotech stocks shot up 9.5% last week, and some stocks much more than that. That makes the sector a great place for short-term momentum plays.
Read More
Should You Invest in this Biotech Stock Before It Goes Public?
There's an intriguing private medical device maker that may soon come public on the NYSE. Here's how you can invest in this biotech stock before its IPO.
Read More
Growth Stocks Poised for Banner 2017
Most growth stocks missed the late-2016 rally, and many have been stuck in neutral for nearly three years. Expect that to change in a big way next year.
Read More